| Autor: |
Izurieta P; GSK, Wavre, Belgium., Scherbakov M; GSK, Moscow, Russian Federation., Nieto Guevara J; GSK, Panama City, Panama., Vetter V; GSK, Wavre, Belgium., Soumahoro L; GSK, Wavre, Belgium. |
| Jazyk: |
angličtina |
| Zdroj: |
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 31; Vol. 18 (1), pp. 2013693. Date of Electronic Publication: 2022 Jan 12. |
| DOI: |
10.1080/21645515.2021.2013693 |
| Abstrakt: |
Otitis media (OM) is a common disease of childhood and available pneumococcal conjugate vaccines (PCVs), with different compositions, could have different impact on OM reduction. This systematic literature review evaluated available data describing the efficacy, effectiveness, and impact of 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and 13-valent PCV (PCV13) on OM outcomes. Statistically significant reductions in all-cause and complicated OM, tympanostomy tube placement and OM-related hospitalizations were consistently observed after the introduction of PHiD-CV and PCV13. Impact studies with data in children <2 years of age using PCV13 report 47-51% and PHiD-CV 34-43% reduction of all-cause OM (primary care, outpatient, ambulatory, emergency department visits) compared to periods before PCV introduction. When the impact of both vaccines is assessed in comparable settings, some studies suggest PHiD-CV may offer better protection against some OM outcomes. Well-designed, head-to-head comparisons are needed to better understand the differences and guide vaccination policies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
